Browse more cannabis research, findings, methods, and limitations.
In 249 first-episode psychosis patients, polygenic risk scores for cannabis use predicted symptom trajectories, suggesting partially independent genetic factors for initiation vs. disorder.
Systematic mapping of 447 studies on cannabis liberalization found massive evidence gaps, with over half of outcomes studied by 3 or fewer papers.
Among 713,290 bariatric surgery patients, cannabis use disorder was linked to 2.24x higher complication risk and 1.3 days longer hospital stays.
Combined literature review and Reddit analysis found mixed evidence on cannabis and male sexual health, with men actively seeking answers online amid conflicting experiences.
Review of cannabinoids for spine surgery pain found mechanistic promise through endocannabinoid receptors but very few clinical studies with variable results.
Umbrella review of 25 systematic reviews found consistent evidence linking recreational cannabis to suicidal ideation and attempts, with dose-response patterns.
Review found cannabinoids target multiple tumor microenvironment components to fight cancer, with several clinical trials now testing these effects in patients.
Pilot study found adults with cannabis use disorder had blunted pleasure responses that personalized scripted imagery could partially restore.
Study validated the DSM-5 craving criterion across cannabis and 5 other substances, finding moderate craving was more predictive of clinical outcomes than severe.
Macaque study found prenatal THC edible exposure changed DNA methylation at autism-linked genes, with 98% of changes occurring in placenta.
Adding EMA to counseling increased mindful awareness in young cannabis users, and higher mindfulness was linked to lower cannabis desire and negative affect.
In 15 ASD children on medical cannabis, 22 salivary lipid biomarkers shifted toward typically developing levels, suggesting inflammation and oxidative stress pathways.
Metabolomics analysis found 65 salivary biomarkers shifted toward typical levels in 15 ASD children on medical cannabis, including inflammation and neurotransmitter markers.
Fatal overdose case involving two potent synthetic cannabinoids, MDMB-4en-PINACA and 4F-ABUTINACA, in a 26-year-old male. Autopsy showed acute cardiac damage.
Longitudinal study found prenatal tobacco and cannabis exposure associated with elevated inflammatory markers (salivary CRP) in children ages 4-6.
Women increasingly use cannabis for endometriosis, pelvic pain, and period cramps, with retrospective data suggesting benefit — but clinical trials are nearly nonexistent and barriers to medical access persist.
Review examines CBD safety profile as an anti-inflammatory agent, noting general tolerability but flagging liver effects, drug interactions, and gaps in long-term data.
Review of cannabinoids for multiple sclerosis finds preclinical promise and some clinical support for spasticity relief, but limited trial data overall.
Controlled fMRI study found THC blunted reward-related brain activity in adults but not adolescents. Adding CBD partially offset the effect in adults.
Case series reported hair regrowth with topical hemp extract containing CBD, THCV, and CBDV over 6 months. No control group.
Tablet-based cognitive test battery detected acute cannabis impairment, with occasional users showing larger deficits than daily users across four cognitive domains.
Umbrella review of 101 meta-analyses found strong evidence for cannabis-psychosis and crash links, moderate therapeutic evidence for select conditions, and weak evidence for most other claims.
12-month study of 323 fibromyalgia patients found medical cannabis reduced pain partly through improvements in sleep and anxiety/depression symptoms.
Rat study found CBD prevented the negative emotional conditioning associated with opioid withdrawal through 5-HT1A serotonin receptor activation.
ABCD Study analysis of ~10,000 children found sleep protects against behavior problems, but prenatal cannabis exposure significantly weakened this protective effect.
EU-GEI study of 1,125 people found those who first used cannabis to cope with negative emotions had higher psychosis risk than those who started for social reasons.
Survey of 415 Canadian military members and veterans at a mental health clinic found cannabis use was common, associated with younger age and PTSD.
CBD and cannabis-inspired terpene blends both improved social behavior in an autism mouse model within 30 minutes of administration.
Legal analysis examines how cannabis industry consolidation and big business entry create barriers for equity programs designed to address prohibition-era harms.
Systematic review of 9 studies (564 patients) found low-quality evidence supporting short-term pain reduction with cannabis in fibromyalgia.
Two case reports show adolescent vaping of nicotine and marijuana during COVID linked to social stressors and mental health symptoms, highlighting need for holistic treatment.
Systematic review of 20 studies found mixed evidence on prenatal cannabis exposure and birth defects, with too few studies per organ system for strong conclusions.
Analysis of 265,000+ pregnancies identified four prenatal substance use patterns including a cannabis-predominant group (4.9%) with elevated depression and anxiety.
Crossover RCT found 1:1 THC:CBD oil significantly reduced chemotherapy-induced nausea in 54 gynecologic cancer patients, though dizziness was common.
National survey of 68,000+ US teens found nondisordered cannabis use (10.2%) associated with doubled odds of depression, suicidal ideation, and academic problems vs. non-use.
Single-cell sequencing study found CBD reprogrammed tumor macrophages and enhanced anti-PD-1 immunotherapy response in a colon cancer mouse model.
Prospective study of 56 patients found cannabis-induced psychosis presents with positive symptoms and improves steadily over one month after cannabis cessation.
Retrospective study of 68 chronic pain patients found a small reduction in opioid prescriptions after starting medical cannabis, with no changes in other healthcare use.
Prospective cohort found late prenatal cannabis exposure associated with higher language scores at 12 months in 69 exposed vs. 138 unexposed infants.
90-day rat toxicology study established CBD safety limits: NOAEL of 460 mg/kg/day (males) and 230 mg/kg/day (females), with most changes reversible.
Meta-analysis of 6 RCTs confirms CBD (Epidiolex) significantly reduces seizures in Dravet, Lennox-Gastaut, and tuberous sclerosis complex, with notable side effects.
Qualitative study of 52 pregnant/lactating cannabis users found information about risks inadequate and clinicians generally unhelpful or judgmental on the topic.
Electron microscopy study found CB1 receptor expression increases in reactive microglia but stays proportionally constant in astrocytes in an Alzheimer's mouse model.
Historical and pharmacological review traces cannabis use for gastrointestinal disorders from ancient medicine to modern endocannabinoid system research.
Largest-ever meta-analysis (183M patients) found cannabis use significantly associated with stroke risk but not heart attack risk — though observational data can't prove causation.
2-year longitudinal study of 401 Hispanic adolescents found poor explicit-risk decision-making predicted escalating cannabis use and related problems.
Systematic review of 28 studies (523,107 patients) found no significant pooled associations between prenatal cannabis exposure and child cognitive or academic outcomes.
Chart review of 110 teens found aripiprazole associated with shorter hospital stays (5.8 vs. 9.7 days) than risperidone for cannabis-related psychosis.
Machine learning and traditional models achieved only modest accuracy predicting cannabis use disorder treatment response in a multi-site trial analysis.
Systematic review of prenatal polysubstance use in the US finds cannabis commonly co-used with other substances, with widely varying prevalence estimates.